Spironolactone and hydrochlorothiazide exert antioxidant effects and reduce vascular matrix metalloproteinase-2 activity and expression in a model of renovascular hypertension

Matrix Metalloproteinase-7 and ADAM-12 (a Disintegrin and Metalloproteinase-12) Define a Signaling Axis in Agonist-Induced Hypertension and Cardiac Hypertrophy

(2009) Xiang Wang et al.   CIRCULATION

Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension

(2009) Michele M. Castro et al.   FREE RADICAL BIOLOGY AND MEDICINE

Xanthine oxidase and mitochondria contribute to vascular superoxide anion generation in DOCA-salt hypertensive rats

(2008) Emilie C. Viel et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

Evidence of early involvement of matrix metalloproteinase-2 in lead-induced hypertension

(2008) Elen Rizzi et al.   ARCHIVES OF TOXICOLOGY

Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats

(2008) Marcio L.L. Martinez et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Cross-Talk Between Mineralocorticoid and Angiotensin II Signaling for Cardiac Remodeling

(2008) An Di Zhang et al.   HYPERTENSION

Oxidative Stress Contributes to Renovascular Hypertension

(2007) E. B. Oliveira-Sales et al.   AMERICAN JOURNAL OF HYPERTENSION

Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats

(2007) Michele M. Castro et al.   ATHEROSCLEROSIS

Apocynin Is Not an Inhibitor of Vascular NADPH Oxidases but an Antioxidant

(2007) Sabine Heumüller et al.   HYPERTENSION

RETRACTED: Activation and silencing of matrix metalloproteinases

(2007) X FU et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Effects of spironolactone on human blood mononuclear cells: mineralocorticoid receptor independent effects on gene expression and late apoptosis induction

(2006) Søren Ulrik Salling Sønder et al.   BRITISH JOURNAL OF PHARMACOLOGY